Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.

Background: Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, inhibits the signals of interleukin-4 and interleukin-13, and has also shown significant efficacy in patients with moderate-to-severe atopic dermatitis (AD), while the effect of it on adverse events remains controversial.

Objective: To assess the influence of dupilumab on adverse events in adults with moderate-to-severe AD.

Method: Randomised controlled trials (RCTs) that compared dupilumab with a placebo for patients with moderate-to-severe AD were searched in the MEDLINE, EMBASE, Web of Science and Cochrane databases.